Latham & Watkins has advised ArchiMed on its acquisition of Suanfarma, which represents the landing of the French company in Spain. A&O advised ICG on the sale
Suanfarma is a Spanish company specialising in the development, production and marketing of ingredients for the pharmaceutical, veterinary and nutritional sectors. This transaction, pending closing, represents the landing of ArchiMed in Spain and the end of the successful investment cycle in Suanfarma of the management companies ICG and ProA Capital, which, by virtue of the same, leave the company’s shareholding.
ArchiMed, a French private equity firm specialising in the healthcare industry, with more than €2.5 billion in assets under management through five funds, expects to continue Suanfarma’s growth and expansion, and that the company could exceed a valuation of €1 billion in the coming years.
The Latham & Watkins cross-border and multidisciplinary team in charge of the transaction has been led by Madrid office corporate partner José Antonio Sánchez-Dafos (pictured) and London partner Farah O’Brien, with the support of associates María Pilar Villanueva, Celia Vega-Penichet, Ori Assa and Marta Portuondo. On behalf of the Spanish office, Finance partner Fernando Colomina, counsel Luis Sánchez and associates Leticia Sitges, in the Regulatory area, and Juan Rodríguez in the Tax area, also participated.
The transaction has also involved several of the firm’s offices, including an international Regulatory and Sanctions team made up of Washington D.C. lawyers Les Carnegie and Ehson Kashmir. Les Carnegie and Ehson Kashfipour, Kiera Murphy in San Diego, and Paul Davies, Charles Claypoole, Michael Green, Amaryllis Bernitsa and Thomas Lane in London.
Allen & Overy advised ICG, shareholder pf Suanfarma, with a team led by partner Íñigo del Val.